Akebia Therapeutics, Inc. AKBA
Updated: 10 Aug 2026
No signal published yet
We already track Akebia Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Akebia Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Akebia Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 5, 2026, Akebia Therapeutics reported its second quarter 2026 financial results, posting $49.1 million in total revenue and $21.3 million in Vafseo net product sales. The company highlighted positive interim results from the VOICE trial demonstrating safety benefits for Vafseo over erythropoiesis-stimulating agents. Additionally, Akebia initiated a Phase 2 basket trial evaluating ebribafusp for rare kidney diseases.
What Firelda Watch includes for Akebia Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Akebia Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Akebia Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more